 |
|
|
| |
REAL-WORLD EFFECTIVENESS OF 12 WEEK ELBASVIR/GRAZOPREVIR (EBR-GZR) IN PATIENTS WITH GENOTYPE 1 (GT1) CHRONIC HEPATITIS C (HCV) AND CHRONIC KIDNEY DISEASE (CKD): RETROSPECTIVE DATA ANALYSES FROM THE TRIO NETWORK
|
| |
| |
Reported by Jules Levin
APASL March 14-18 2018 New Delhi
C. Nwankwo1; B. Bacon2; M. Curry3; S.L. Flamm4; S. Milligan5; N. Tsai6 and N. Afdhal2
1Merck & Co., Inc., Kenilworth, NJ USA; 2Saint Louis University School of Medicine, St. Louis, MO; 3Beth Israel Deaconess Medical Center, Boston, MA; 4Northwestern University Feinberg School of Medicine, Chicago IL; 5Trio Health Analytics ,La Jolla, CA; and 6Queens Medical Center, University of Hawaii, Honolulu, HI USA.
|
| |
|
|
|
|
|
